$BNTX News

UBS Upgrades BioNTech to Buy, Raises Price Target to $135

Bernstein Initiates Coverage On BioNTech with Market Perform Rating, Announces Price Target of $96

BioNTech (NasdaqGS:BNTX) Valuation After New Supervisory Board Appointments Focused On Oncology And Commercial Expertise

BioNTech Expands Supervisory Board To Support Oncology Pipeline And Commercial Plans

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

BioNTech SE 2026 Q1 - Results - Earnings Call Presentation

BioNTech Announces New ADS Repurchase Program

Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $158

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

Wells Fargo Maintains Overweight on BioNTech, Lowers Price Target to $140

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

BioNTech Q1 Earnings Call Highlights

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BioNTech Affirms FY2026 Sales Guidance of $2.328B-$2.678B vs $2.560B Est

BioNTech Q1 Adj. EPS $(2.28) Beats $(2.52) Estimate, Sales $138.000M Miss $214.620M Estimate

HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $130 Price Target

Why BioNTech (BNTX) Is Up 9.2% After Strong Phase 2 HER2 ADC Data In Endometrial Cancer

BioNTech (BNTX) Price Target Raised Following Successful T-Pam Data